The methodological framework developed here could be applied to investigate the dynamical consequences of other spatial heterogeneities, which in the case of AD and bvFTD include glucose metabolism, tau and amyloid PET imaging, and multimodal allostatic markers (Engler et al., 2008; Foster et al., 2007; Jack et al., 2018; Mosconi et al., 2008; Nordberg, 2004; Migeot et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.